Needham & Company LLC Issues Pessimistic Forecast for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price

Collegium Pharmaceutical (NASDAQ:COLL) had its price target reduced by Needham & Company LLC from $56.00 to $54.00 in a report released on Thursday,Benzinga reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 29.59% from the company’s current price.

COLL has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $60.00 target price (up from $46.00) on shares of Collegium Pharmaceutical in a research report on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research note on Tuesday, February 10th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Finally, Barclays lowered their price target on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $53.00.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $41.67 on Thursday. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 24.37 and a beta of 0.64. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $50.79. The stock’s 50 day simple moving average is $46.50 and its two-hundred day simple moving average is $42.03. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The business had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 104.09%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the business posted $1.77 earnings per share. As a group, equities analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. The trade was a 14.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several large investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund increased its position in shares of Collegium Pharmaceutical by 1.6% during the third quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock worth $605,000 after acquiring an additional 278 shares during the period. Vident Advisory LLC increased its holdings in Collegium Pharmaceutical by 1.9% during the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock worth $541,000 after purchasing an additional 281 shares during the period. Quadrant Capital Group LLC raised its position in Collegium Pharmaceutical by 4.2% during the 4th quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after purchasing an additional 282 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Collegium Pharmaceutical by 9.6% in the 4th quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 285 shares during the period. Finally, Atom Investors LP grew its position in shares of Collegium Pharmaceutical by 5.0% during the 4th quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after buying an additional 294 shares in the last quarter.

More Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Company expects strong growth for its lead product Jornay PM (targets ~31% Jornay revenue growth for 2026) and says it is advancing its pain portfolio—this supports longer‑term top‑line momentum. Article Title
• Positive Sentiment: Needham & Company slightly lowered its price target from $56 to $54 but maintained a “buy” rating, signaling analyst confidence that shares retain upside from current levels. Article Title
• Positive Sentiment: Collegium reported record full‑year net revenues of $780.6M (up 24% YoY) and Q4 net revenues of $205.4M (up 13% YoY), demonstrating solid revenue growth even as profit metrics were mixed. Article Title
• Neutral Sentiment: FY2026 revenue guidance was reiterated/updated to roughly $805M–$825M (in line with consensus), which reduces guidance risk but provides limited upside surprise potential. Article Title
• Neutral Sentiment: Collegium announced a partnership with Boston Legacy FC focused on sensory inclusion and ESG initiatives — positive for brand/ESG profile but limited near‑term financial impact. Article Title
• Neutral Sentiment: Several analyst writeups and a multi‑rating deep dive were published (collecting views from five analysts); useful for tracking sentiment but no consensus rating shock reported. Article Title
• Negative Sentiment: Earnings missed consensus: reported EPS was below expectations (reported $2.04 vs. ~$2.20 expected) and Q4 revenue slightly missed estimates—this is the primary driver of the share weakness today. Article Title
• Negative Sentiment: Earnings call / transcripts highlighted the miss and prompted investor questions on cadence and margins—market reaction to the tone of the call amplified selling pressure. Article Title
• Neutral Sentiment: Short‑interest data posted for February appears to contain errors (reported as 0 shares / NaN increase), so there’s no clear signal from short interest trends at this time. (Data likely unreliable.)
• Negative Sentiment: Trading showed elevated volume versus average as investors sold into the earnings print, contributing to the downward price move today.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.